<div>
  <p>
  </p>
  <ul>
    <li>
      <p>
        Genetic testing, CDx, and PGx provider Thermo Fisher Scientific has priced an offering of USD 2.5 billion worth of senior notes.
      </p>
    </li>
    <li>
      <p>
        The split of these with reference to issue prices involves: USD 1 billion worth of notes with an interest rate of 5% due in 2023 priced at&nbsp; 99.931% of the principal value, USD 1 billion of notes with an interest rate of 5% due in 2029 priced at 99.772% of the principal value, and USD 500 million of notes due 2034, with an interest rate of 5.2% priced at 99.846% of the principal. The notes carry interest on a semi-annual basis.
      </p>
    </li>
    <li>
      <p>
        Thermo Fisher expects to use the proceeds for general corporate purposes, including acquisitions and repayment/refinancing of debt and operational and capital expenditures.
      </p>
    </li>
    <li>
      <p>
        The company expects to close the offering on or around December 5. The joint bookrunning managers for the notes are BofA Securities, Morgan Stanley, US Bancorp Investments, and Wells Fargo Securities.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.genomeweb.com/business-news/thermo-fisher-scientific-offering-25b-senior-notes">
      Genome Web
    </a>
  </p>
  <p>
  </p>
</div>


Precision Medicine

INCUMBENTS_PRESENT

<div>
<p>Genetic testing, CDx, and PGx provider Thermo Fisher Scientific has priced an offering of USD 2.5 billion worth of senior notes.</p>
<p>The split of these with reference to issue prices involves: USD 1 billion worth of notes with an interest rate of 5% due in 2023 priced at 99.931% of the principal value, USD 1 billion of notes with an interest rate of 5% due in 2029 priced at 99.772% of the principal value, and USD 500 million of notes due 2034, with an interest rate of 5.2% priced at 99.846% of the principal. The notes carry interest on a semi-annual basis.</p>
<p>Thermo Fisher expects to use the proceeds for general corporate purposes, including acquisitions and repayment/refinancing of debt and operational and capital expenditures.</p>
<p>The company expects to close the offering on or around December 5. The joint bookrunning managers for the notes are BofA Securities, Morgan Stanley, US Bancorp Investments, and Wells Fargo Securities.</p>
</div>

Thermo Fisher Scientific prices offering of USD 2.5 billion in senior notes to fund general corporate requirements

<div>
  <ul>
    <li>
      <p>Thermo Fisher Scientific (Thermo) has offered to acquire Olink, a Swedish provider of proteomics analysis equipment and services for tracking down and developing biomarkers.</p>
    </li>
    <li>
      <p>Through a deal worth USD 3.1 billion, Thermo has agreed to pay USD 26 for each of Onlik’s shares. Olink has around USD 143 million cash in hand, alongside the company’s international operations in Boston, Tokyo, and Shanghai. The acquisition is intended to extend Thermo’s reach in protein research.</p>
    </li>
    <li>
      <p>Thermo is a provider of medical equipment, analytical instruments, reagents and consumables, software, and services to tackle complex analytical challenges in research, diagnostics, and clinical laboratories. It offers solutions for cellular analysis and biology, flow cytometry, and synthetic biology. The company has a range of products, which include technologies for mass spectrometry, genetic sequencing, electron microscopy, protein, and molecular biology research.</p>
    </li>
    <li>
      <p>Olink develops and markets its unique technology for protein analysis in human protein biomarker research. Olink’s proprietary Proximity Extension Assay (PEA) technology enables researchers to analyze large numbers of proteins with high-throughput analysis, exceptional data quality, and minimal sample consumption.</p>
    </li>
  </ul>
</div>

Thermo Fisher Scientific to absorb Swedish proteomics player Olink in USD 3.1 billion deal

Making meat sustainable over the long term.

All Updates

Thermo Fisher Scientific prices offering of USD 2.5 billion in senior notes to fund general corporate requirements

Thermo Fisher Scientific to absorb Swedish proteomics player Olink in USD 3.1 billion deal

Aleph Farms partners with Thermo Fisher Scientific to establish a growth media supply chain

Thermo Fisher Scientific receives FDA approval for use of Oncomine Dx assay with Janssen drug

Precision Medicine

Thermo Fisher Scientific prices offering of USD 2.5 billion in senior notes to fund general corporate requirements

Contact us